Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Dispatch

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022

Ramona Groenheit, Philip Bacchus1, Ilias Galanis1, Klara Sondén, Ioana Bujila, Tatiana Efimova, Fredrik Garli, Oskar Karlsson Lindsjö, Mikael Mansjö, Elin Movert, Aleksandra Pettke, Marie Rapp, Maike Sperk, Sandra Söderholm, Karin Valentin Asin, Sarah Zanetti, Maria Lind Karlberg, Andreas Bråve, Kim Blom2Comments to Author , and Jonas Klingström2
Author affiliations: Public Health Agency of Sweden, Solna, Sweden (R. Groenheit, I. Galanis, K. Sondén, I. Bujila, T. Efimova, F. Garli, O. Karlsson Lindsjö, M. Mansjö, E. Movert, A. Pettke, M. Rapp, M. Sperk, S. Söderholm, K. Valentin Asin, S. Zanetti, M. Lind Karlberg, A. Bråve, K. Blom, J. Klingström); Swedish Armed Forces, Umeå, Sweden and Lund University, Lund, Sweden (P. Bacchus); Karolinska Institutet, Stockholm, Sweden (K. Sondén, M. Sperk, K. Blom, J. Klingström); Linköping University, Linköping, Sweden (J. Klingström)

Main Article

Figure

Flowchart of study participant enrollment and collected and analyzed samples in a study of prevalence of SARS-CoV-2 Omicron infection despite high seroprevalence, Sweden, 2022. A) Surveys performed during March 21–25. B) Surveys performed September 26–29. Point prevalence and Omicron subvariant data from the September study was published previously (6).

Figure. Flowchart of study participant enrollment and collected and analyzed samples in a study of prevalence of SARS-CoV-2 Omicron infection despite high seroprevalence, Sweden, 2022. A) Surveys performed during March 21–25. B) Surveys performed September 26–29. Point prevalence and Omicron subvariant data from the September study was published previously (6).

Main Article

References
  1. Tegally  H, Moir  M, Everatt  J, Giovanetti  M, Scheepers  C, Wilkinson  E, et al.; NGS-SA consortium. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28:1785–90. DOIPubMedGoogle Scholar
  2. Dejnirattisai  W, Shaw  RH, Supasa  P, Liu  C, Stuart  AS, Pollard  AJ, et al.; Com-COV2 study group. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399:234–6. DOIPubMedGoogle Scholar
  3. Tuekprakhon  A, Nutalai  R, Dijokaite-Guraliuc  A, Zhou  D, Ginn  HM, Selvaraj  M, et al.; OPTIC Consortium; ISARIC4C Consortium. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13. DOIPubMedGoogle Scholar
  4. Blom  K, Marking  U, Havervall  S, Norin  NG, Gordon  M, García  M, et al. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022;22:943–5. DOIPubMedGoogle Scholar
  5. Groenheit  R, Beser  J, Kühlmann Berenzon  S, Galanis  I, van Straten  E, Duracz  J, et al. Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020. BMC Infect Dis. 2022;22:861. DOIPubMedGoogle Scholar
  6. Groenheit  R, Galanis  I, Sondén  K, Sperk  M, Movert  E, Bacchus  P, et al. Rapid emergence of omicron sublineages expressing spike protein R346T. Lancet Reg Health Eur. 2023;24:100564. DOIPubMedGoogle Scholar
  7. Blom  K, Havervall  S, Marking  U, Norin  NG, Bacchus  P, Groenheit  R, et al. Infection rate of SARS-CoV-2 in asymptomatic healthcare workers, Sweden, June 2022. Emerg Infect Dis. 2022;28:2119–21. DOIPubMedGoogle Scholar
  8. Office for National Statistics. United Kingdom. Coronavirus (COVID-19) [cited 2022 December 1]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases
  9. Erikstrup  C, Laksafoss  AD, Gladov  J, Kaspersen  KA, Mikkelsen  S, Hindhede  L, et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. Lancet Reg Health Eur. 2022;21:100479. DOIPubMedGoogle Scholar
  10. Ott  R, Achenbach  P, Ewald  DA, Friedl  N, Gemulla  G, Hubmann  M, et al. SARS-CoV-2 seroprevalence in preschool and school-age children. Dtsch Arztebl Int. 2022;119:765–70. DOIPubMedGoogle Scholar
  11. Woodbridge  Y, Amit  S, Huppert  A, Kopelman  NM. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. Nat Commun. 2022;13:6706. DOIPubMedGoogle Scholar
  12. Hachmann  NP, Miller  J, Collier  AY, Ventura  JD, Yu  J, Rowe  M, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387:86–8. DOIPubMedGoogle Scholar
  13. Qu  P, Evans  JP, Faraone  JN, Zheng  Y-M, Carlin  C, Anghelina  M, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31:9–17.e3. DOIPubMedGoogle Scholar
  14. Sheward  DJ, Kim  C, Fischbach  J, Sato  K, Muschiol  S, Ehling  RA, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis. 2022;22:1538–40. DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: April 17, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external